Professor Robert Rosenson
Icahn School of Medicine at Mount Sinai, New York City (United States of America)
Membership:
FESC Member
Biography
Robert S. Rosenson, MD, is Professor of Medicine at the Icahn School of Medicine at Mount Sinai, and Director of Metabolism and Lipids for the Mount Sinai Health System, New York, New York. He received his medical degree at Tulane University, New Orleans, Louisiana, and went on to complete his residency in internal medicine at Brigham and Women’s Hospital, Boston, Massachusetts, followed by a fellowship in cardiovascular medicine at The University of Chicago, Chicago, Illinois.
Dr Rosenson is a Fellow of ACC, ACP, ACCP, ESC and NLA. He is the recipient of numerous awards and honors, including New York Top Doc from 2015 to 2021, USA Top Doctor in 2019, recipient of the Simon Dack Award for outstanding scholarship by JACC in 2015, 2016, 2017, 2019, 2020 and 2022.In 2017, UpToDate recognized him for 20 years of Outstanding Contributions as Editor. In 2019, he was awarded the Clinician Educator Award from the National Lipid Association.
Contributor content
Presentation
Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2
Presentation
Recurrent atherosclerotic cardiovascular disease events preventable with guideline recommended lipid-lowering treatment following myocardial infarction
Presentation
Assessment of cardiovascular disease risk using different thresholds to define high risk on the pooled cohort equations
Presentation
Presentation
Panel discussion and Q&A - Cardiovascular risk: the dangers of blood pressure and low-density lipoprotein cholesterol.
Presentation
The burden of hypertension and high cholesterol – Impact of non-compliance and failure to reach goals.
Presentation
Adherence to intensive medical management in the year following hospitalization for myocardial infarction
Presentation
Presentation
Statin use and dose by low-density lipoprotein cholesterol level in U.S. commercially insured patients with type 2 diabetes
Presentation
